TRAWS PHARMA, INC.
TRAWS PHARMA, INC. (ONTX): 9 pipeline candidates · ~5 mo cash runway · 11 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.5 months
5% dilution
Lead: Phase 3
9 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for TRAWS PHARMA, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$3.1M
Quarterly Burn
$2.6M
Runway
4.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (9 candidates)
| Drug | Phase |
|---|---|
| 83-0060 | Phase 1 |
| influenza a/france/759/2021 virus | Phase 2 |
| narazaciclib | Phase 1 |
| paxlovid | Phase 2 |
| ratutrelvir | Phase 2 |
| ratutrelvir non-randomised | Phase 2 |
| rigosertib | Phase 3 |
| tivoxavir marboxil | Phase 2 |
| trx-100 | Phase 2 |
Frequently asked questions
How many drug candidates are in TRAWS PHARMA, INC.'s pipeline?
TRAWS PHARMA, INC. (ONTX) has 9 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is TRAWS PHARMA, INC.'s lead drug candidate?
TRAWS PHARMA, INC.'s most advanced tracked candidate is 83-0060 (Phase 1) for Healthy Volunteers Only.
What is TRAWS PHARMA, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, TRAWS PHARMA, INC. has approximately 4.5 months of cash runway.
Who is the CEO of TRAWS PHARMA, INC.?
Iain Dukes Iain is the chief executive officer of TRAWS PHARMA, INC. (ONTX).
Get the full picture on TRAWS PHARMA, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.